ADVERTISEMENT

Antidepressants: Good Drugs or Good Marketing?

A scandal over hidden data about adolescent suicide lights a dark corner of our drug approval system

(Further Reading)

  • Suppression of Mosholder’s findings and testimony is documented by Anna Wilde Mathews’s article “In Debate over Antidepressants, FDA Weighed Risk of False Alarm Doubting Data on Suicide and Kids” in Wall Street Journal; May 25, 2004. Viewable at www.ahrp.org/infomail/04/05/25.html
  • Drug Company Experts Advised Staff to Withhold Data about SSRI Use in Children. Wayne Kondro in Canadian Medical Association Journal, Vol. 170; No. 5; March 2, 2004. Available online at www.cmaj.ca/cgi/content/full/170/5/783

This article was originally published with the title "Perspectives: Antidepressants: Good Drugs or Good Marketing."

or subscribe to access other articles from the December 2004 publication.
Digital Issue $7.95
Digital Subscription $19.99 Subscribe
Share this Article:

Comments

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Scientific American Holiday Sale

Scientific American Mind Digital

Get 6 bi-monthly digital issues
+ 1yr of archive access for just $9.99

Hurry this offer ends soon! >

X

Email this Article

X